BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer (Q43497738)
Jump to navigation
Jump to search
scientific article published on 16 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer |
scientific article published on 16 July 2013 |
Statements
1 reference
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer (English)
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Andrew Stone
1 reference
Fatima Valdes-Mora
1 reference
C Marcelo Sergio
1 reference
David Gallego-Ortega
1 reference
C Elizabeth Caldon
1 reference
Christopher J Ormandy
1 reference
Robert I Nicholson
1 reference
Elizabeth A Musgrove
1 reference
16 July 2013
1 reference
1 reference
1 reference
Identifiers
1 reference